First- and second-generation antipsychotics and the concept of "atypicality" implications for clinical practice

Psychopharm Review

Volumn 44, Issue 11, 2009, Pages 81-88

  Chen, Hong ^a,b   Tandon, Rajiv ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; ILOPERIDONE; OLANZAPINE; PALIPERIDONE; PEROSPIRONE; PERPHENAZINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTENSION; MEDICAL DECISION MAKING; METABOLIC DISORDER; MOOD DISORDER; NEGATIVE SYNDROME; POSITIVE SYNDROME; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT RESPONSE; WEIGHT;

EID: 77949914459     PISSN: 19369255     EISSN: None     Source Type: Trade Journal    
DOI: 10.1097/01.IDT.0000360999.60168.a4     Document Type: Review

References (47)

1. Nasrallah HA, Tandon R. Classic antipsychotic medications. In: Nemeroff C, SchatzbergA, eds. American Psychiatric Press Textbook of Psychopharmacology, 4th ed.Washington, DC:American Psychiatric Press; 2009:533-554.
2. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment- resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-796.
3. ChakosM, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatmentresistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158(4):518-526.
4. Meltzer HY,Alphs L, GreenAI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60(1):82-91.
5. EssaliA,Al-Haj HA, Li C, et al. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev January 21, 2009;(1):CD000059.
6. MillerAL, Hall CS, Buchanan RW, et al. The TexasMedication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004;65(4):500-508.
7. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001;52:503-517.
8. Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64(Suppl 12):5-19.
9. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998;32(3-4):215-228.
10. Meltzer HY.What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol 2004;4(1):53-57.
11. Heres S, Davis J, Maino K, et al.Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-headcomparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163(2):185-194.
12. Lieberman JA, Stroup ST,McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl JMed 2005;353(12):1209- 1223.
13. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of effect on quality of life of second- vs. firstgeneration antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006;63(10):1079-1087.
14. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior antipsychotic treatment. Am J Psychiatry 2006;163(4):600-610.
15. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163(4):611-622.
16. Keefe RSE, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007;64(6):633-647.
17. Swartz MS, Perkins DO, Stroup ST, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007;164(3):428-436.
18. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163(12):2080-2089.
19. Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32(4):715-723.
20. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia (TEOSS) study. Am J Psychiatry 2008;165(11):1420-1431.
21. Kahn RS, FleischhackerWW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008;371(9618):1085-1097.
22. Webb T, Tandon R. Antipsychotic treatment of first-episode or early-onset schizophrenia. Curr Psychiatry Rep 2009; 11(4):261-263.
23. Moller HJ. Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study. Eur Arch Psychiatry Clin Neurosci 2005;255(6):371-372.
24. Meltzer HY, BoboWV. Interpreting the efficacy findings in the CATIE study: what the clinician should know. CNS Spectrums 2006;11(Suppl 7):14-24.
25. Tandon R, CarpenterWT, Davis JM. First- and secondgeneration antipsychotics: learning from CUtLASS and CATIE. Arch Gen Psychiatry 2007;64(8):977-978.
26. Lewis S, Lieberman J. CATIE and CUtLASS: Can we handle the truth? Br J Psychiatry 2008;192(3):161-163.
27. Tandon R, Belmaker RH, GattazWF, et al.World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100(1-3):20-38.
28. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321(7273):1371-1376.
29. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60(6):553-564.
30. Tandon R, FleischhackerWW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005;79(2-3):145-155.
31. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41.
32. Tandon R, Nasrallah HA. Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics-author reply. Arch Gen Psychiatry 2006;63(8):937-939.
33. Leucht S,Arbter D, Engel RR, et al. How effective are second- generation antipsychotic drugs?A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009;14(4):429-447.
34. Tuunainen A,Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 2002;56(1-2):1-10.
35. Kane JM, Meltzer HY, CarsonWH, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multi-center, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007;68(2):213-223.
36. Hugenholtz GW, Heerdink ER, Stolker JJ, et al. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry 2006;67(6):897-903.
37. Tandon R. Comparative effectiveness of antipsychotics in the treatment of schizophrenia: what CATIE (phase 1) tells us-Part 1. Int Drug Ther Newsl 2006;41(7):51-58.
38. Tandon R. Comparative effectiveness of antipsychotics in the treatment of schizophrenia: what CATIE (phases 1 and 2) tells us-Part 2. Int Drug Ther Newsl 2006;41(9):67-74.
39. Leucht S,Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-1589.
40. Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomized trial. Br J Psychiatry 2008;193(4):279-288.
41. Marder SR, Essock SM, Miller AM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161(8):1334-1349.
42. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93.
43. Constantine RJ, Richard SM, Surles RC, et al. Optimizing pharmacotherapy of schizophrenia: tools for the psychiatrist. Curr Psychosis Ther Rep 2006;4:5-11.
44. Constantine RJ, Tandon R. Antipsychotics equivalent? CUtLASS renews the debate. Curr Psychiatry 2007;6:58-78.
45. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts": what we know in 2008, part 1: Overview. Schizophr Res 2008;100(1-3):4-19.
46. Lehman AF. Leaping tall buildings: the science-to-service gap in schizophrenia treatment. Schizophr Bull 2009;35(4): 659-660.
47. Drake RE, Essock SM. The science-to-service gap in realworld schizophrenia treatment: the 95% problem. Schizophr Bull 2009;35(4):677-678.